Clinical Trial Search

Primary: Mean Overall Response Score (ORS) — -0.74; -0.75; -0.64 score on a scale

Primary: Expanded Disability Status Scale (EDSS) Improvement — 3.4; 3.3; 2.5; 3.7 units on a scale

Primary: Effect on Cerebral Blood Flow in White Matter, Gray Matter, Deep White Matter, Deep Gray Matter, and Thalamus — 8.55; 5.12; 5.78; 2.06 Percentage of change in CBF

Primary: Change in the Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) From Baseline to Treatment Phase — -0.13; -1.04 units on a…

Primary: Time to Onset of Clinical Disability Progression (CDP) Sustained for at Least 12 Weeks During the Double-Blind Treatment Period — NA; NA weeks

Primary: Change in Mobility: Timed 25 Foot Walk — -0.39; -0.30 feet per second — p=0.51

Primary: Time to Confirmed Disease Progression (CDP) — NA; NA weeks — p=0.1442

Primary: Area Under the Curve (AUC) of the Combinatorial Weight-Adjusted Disability Score (CombiWISE) — 1.55; 0.80; 0.46; 0.89 units on a scale * year

Primary: Expanded Disability Status Scale (EDSS) Plus — 17; 17 Participants — p=1.0

Primary: Covariate-adjusted Mean Rate of Change in Brain Atrophy Over 96 Weeks as Measured by Brain Parenchymal Fraction (BPF). — -0.00168; -0.00392 ratio — p=0.04

Primary: Rate of Change in Brain Parenchymal Fraction — 0.107; -0.355 percentage of change in brain volume — p=0.346

Primary: Number of Participants With Treatment-emergent Adverse Events — 18 Participants

Primary: Brain Atrophy by MRI — -0.4; -1.3 whole brain percent volume change

Primary: Summary of Raw Number of Cumulative Combined Unique Active Lesions in Patients With Relapsing Remitting Multiple Sclerosis by Visit and Treatment — 2.4; 3.2; 3.9; 5.4…

Primary: Kinematics — 15.5; 10 degrees

Primary: Change of Score in Motor Examination (ME) of the Unified MSA Rating Scale (UMSARS-ME) From V1 to V7. — 5.66; 6.60 score on a scale — p=0.51

Primary: Percentage Change in Whole Brain Volume — 0.288; 0.584 percentage of brain volumen change — p=0.003

Primary: Number of Participants Classified as Upper Limb Responders on the 9 Hole Peg Test (9HPT) — 4; 3; 58; 59 Participants

Primary: Comfortable Walking Speed — .45; .60; .52; .67 meters per second — p=.405

Primary: Proportion of Research Cohort Subjects Referred Into a Clinical Trial or Offered Treatment With an Appropriate Second-line Therapy. — 178 Participants

Primary: Change in Patient Quality of Life as Measured by the EuroQol 5-D (EQ-5D) Scale Between Baseline (Visit 1) and 1 Year (Visit 4) — 1; 0.5; 0.5; 0 units on a scale — p=0.59

Primary: Number of Adverse Events up to Six Months Post-treatment — 43; 0 Adverse events

Primary: Adherence — 2; 6; 10; 12 Participants

Primary: Number of Adverse Events Reported Since Baseline Visit That Are Related to N-acetyl Cysteine. — 12; 6 adverse events

Primary: Percentages of Patients With Treatment-emergent Adverse Events (TEAEs) or Treatment-emergent Serious Adverse Events (TESAEs) — 100; 100; 88.9; 100 percentage of…

Primary: Annualized Confirmed Relapse Rate — 0.202; 0.290 relapses per year — p=0.0003

Primary: Mean Preload Phase Duration (PLD) — 0.152; 0.238; 0.163; 0.202 seconds

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Expanded Disability Status Score — 2.9; 2.6 score on a scale

Primary: Treatment Satisfaction Questionnaire for Medication (TSQM) Version 1.4 - Assessment of Global Satisfaction Subscale Score With Teriflunomide Treatment at Week 48 — 68.17…